CTOs on the Move

Kitsap Mental Health Services

www.kitsapmentalhealth.org

 
A happier, healthier you is our goal. Kitsap Mental Health Services provides comprehensive, compassionate and people-centered care.
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million

Executives

Name Title Contact Details

Similar Companies

NextPhase Medical Devices

NextPhase Medical Device — Medical Device Contract Manufacturing Company–Your single source contract manufacturing company for medical device design, development, manufacturing, assembly, and complete supply chain management. We specialize in Sterile S...

The Nature`s Bounty Corporation

The Nature`s Bounty Co. has a history of championing health and wellness tracing back 145 years. Putting science and the highest quality standards at the heart of our business, the brands of The Nature`s Bounty Co. are some of the most trusted in the world. Always motivated by our commitment to excellence, our vision for health and wellness has inspired leading brands such as Nature`s Bounty, Sundown Naturals, Solgar, Holland & Barrett, Osteo Bi-Flex, Ester-C, MET-Rx, Pure Protein, Balance, Body Fortress, Puritan`s Pride and Organic Dr., among others. As a leading global manufacturer, marketer, distributor and retailer of vitamins, nutritional supplements, sports & active nutrition and ethical beauty products, The Nature`s Bounty Co. is committed to supporting wellness in all its forms.

Concord

Concord is a Atlanta, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Regulatory and Clinical Research Institute

Regulatory and Clinical Research Institute, Inc. is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ascentage Pharma

Ascentage Pharma is a globally-focused, clinical-stage biopharmaceutical company developing novel small molecule therapies for cancers, hepatitis B and age-related diseases. Based on breakthrough technology from the University of Michigan, the Company`s expertise is in designing therapeutics that inhibit protein-protein interactions to restore apoptosis, or programmed cell death, in cancers. Ascentage has built a rich pipeline of six clinical candidates, including a novel, highly potent Bcl-2/Bcl-xL inhibitor, APG-1252, as well as candidates aimed at IAP and MDM2-p53 pathways, and next-generation tyrosine kinase inhibitors.